BRIEF-Merck Says Keytruda Cuts Risk of Progression or Death by 43% in dMMR Endometrial Cancer

6

Oct 26 (Reuters) – Merck & Co Inc: * KEYTRUDA® (PEMBROLIZUMAB) AS MONOTHERAPY REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 43% FOR CERTAIN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)